Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling

Induction of IL-17+ T Cell Trafficking and Development by IFN- : Mechanism and Pathological Relevance in Psoriasis

(2014) I. Kryczek et al.   JOURNAL OF IMMUNOLOGY

Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis

(2013) Andrew Johnston et al.   HUMAN MOLECULAR GENETICS

Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation

(2013) A. Johnston et al.   JOURNAL OF IMMUNOLOGY

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

(2012) U. Mrowietz et al.   BRITISH JOURNAL OF DERMATOLOGY

Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24

(2012) F. Wang et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

(2012) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

CD8+ T Cells in the Lesional Skin of Atopic Dermatitis and Psoriasis Patients Are an Important Source of IFN-γ, IL-13, IL-17, and IL-22

(2012) DirkJan Hijnen et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneity of Inflammatory and Cytokine Networks in Chronic Plaque Psoriasis

(2012) William R. Swindell et al.   PLoS One

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

(2011) J. Barker et al.   BRITISH JOURNAL OF DERMATOLOGY

Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis

(2010) Lisa C. Zaba et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

EGFR and IL-1 Signaling Synergistically Promote Keratinocyte Antimicrobial Defenses in a Differentiation-Dependent Manner

(2010) Andrew Johnston et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis

(2010) Andrea Chiricozzi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis

(2010) Pieter C. M. Res et al.   PLoS One

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

(2009) Lisa C. Zaba et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effect of RNA quality on transcript intensity levels in microarray analysis of human post-mortem brain tissues

(2008) Tatiana Popova et al.   BMC GENOMICS

The impact of psoriasis on health care costs and patient work loss

(2008) Joseph F. Fowler et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY